Dashboard

Kymera Therapeutics, Inc.

KYMRNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$9.5B

Price$115.4752w $37.68 – $127.31

Conviction3/ 5

Revenue (TTM)$105M

Revenue growth YoY+134.8%

P/E (trailing)—

Gross margin102.0%

Operating margin-333.5%

Net margin-285.4%

52w price change+167.7%

Next earningsNov 3, 2026

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

Sep 16
Trial initiationClinicalTrials.gov
Phase 1 trial NCT07823205 initiated to evaluate oral formulations of KT-621; recruiting.
Sep 4
Ownership changeSEC
SEC Form 4 insider transaction filing.
Aug 17
Trial initiationClinicalTrials.gov
Kymera initiates Phase 2 trial (NCT07323654) of KT-621 in moderate to severe eosinophilic asthma; recruiting status as of 2026-08-17.
Aug 5
Financial resultsSEC
Kymera Therapeutics files 8-K (items 2.02, 9.01) disclosing financial results.
Jul 27
LeadershipSEC
8-K filed with items 5.02, 7.01, 9.01 covering officer or director changes and related exhibits.
Jul 27
Ownership changeSEC
SEC Form 4 filed reporting insider transaction in KYMR shares.
Jul 7
Ownership changeSEC
Form 4 filing reporting change in beneficial ownership.
Jul 2
Ownership changeSEC
SEC Form 4 insider transaction filing.
Jul 2
Ownership changeSEC
SEC Form 4 insider ownership filing.
Jul 2
Ownership changeSEC
SEC Form 4 insider ownership filing.
Jun 30
Ownership changeSEC
SEC Form 4 insider transaction filing
Jun 30
Ownership changeSEC
SEC Form 4 insider transaction filing.
Jun 30
Trial initiationClinicalTrials.gov
Phase 2 trial (NCT07217015) of KT-621 in moderate to severe atopic dermatitis updated to active, not recruiting.
Jun 30
Trial initiationClinicalTrials.gov
Phase 2 long-term extension study (NCT07677059) of KT-621 in asthma now recruiting participants.
Jun 29
Trial initiationClinicalTrials.gov
Kymera initiates Phase 2 trial (NCT07323654) of KT-621 in moderate to severe eosinophilic asthma; recruiting status.
Jun 26
Ownership changeSEC
SEC Form 4 insider ownership document filed
Jun 25
Ownership changeSEC
SEC Form 4 filing for change in beneficial ownership.
Jun 25
Ownership changeSEC
SEC Form 4 filing on change in beneficial ownership.
Jun 25
OtherSEC
8-K filing (items 7.01/8.01/9.01) on 2026-06-25
Jun 25
Ownership changeSEC
SEC Form 4 insider transaction filing.

Not financial advice — research and opinion only. Disclosures